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ABSTRACT 
 
Background: Accurate measurement of patient reported outcomes (PROs) is 
crucial to understanding how poor health impacts quality of life. PROs are 
particularly important in chronic diseases such as systemic lupus 
erythematosus (SLE), where disease manifestations are protean and objective 
measures may not capture patient centered domains. Patient Reported 
Outcome Measurement Information System (PROMIS) offers dynamic 
computerized adaptive tests (CATs) which have the potential to efficiently and 
accurately measure PROs that are relevant to SLE patients.  
 
Objectives: The aims of this study were to: 1) assess the feasibility of 
administering PROMIS CATS to SLE outpatients; 2) assess the validity of 
PROMIS CATs by correlating them with legacy PRO measures; 3) correlate 
PROMIS CATs with standard measures of SLE disease activity and organ 
damage; 4) assess retest reliability of PROMIS CATs. 
 
Methods: Adults meeting American College of Rheumatology SLE 
classification criteria were recruited from a SLE Center of Excellence. Subjects 
completed the Short Form-36 (SF-36), LupusQoL-US, and selected PROMIS 
CATs in domains of physical, mental and social health. SLE disease activity, 
flare, and damage were evaluated with the SELENA-SLEDAI and SLICC-ACR 
damage index. Subjects self-reported demographic information, relevant 
comorbid conditions, and their subjective experience completing the survey. 
PROMIS CATs were compared with disease activity, damage, and similar 
domains in legacy instruments using Spearman correlations (r). Retest 
  
reliability was evaluated among subjects reporting stable SLE activity at two 
assessments one week apart using intraclass correlation coefficients (ICC). 
 
Results: Of 238 outpatients approached, 204 (86%) completed at least one 
assessment, with 164 (80%) completing the assessment offsite. One hundred 
and sixty-two subjects (79%) completed a retest. There were no significant 
differences in demographic or clinical characteristics between those who 
completed the initial assessment and those who did not. Flaring patients 
completed the retest assessment less frequently (p = 0.03). Subjects found 
the questions relevant and validating. PROMIS CATs showed favorable 
performance characteristics and moderate to strong correlations with similar 
domains in both legacy instruments (r = 0.49 to 0.83, p < 0.0001). However, 
correlations between PROMIS CATs and the SELENA-SLEDAI and SLICC-
ACR damage index were generally weak and statistically insignificant. 
PROMIS CAT retest ICCs were good to excellent, ranging from 0.72 to 0.88. 
 
Conclusion: To our knowledge, these data are the first to show that PROMIS 
CATs can be successfully administered to a diverse cohort of SLE patients at 
the point of care or remotely, and are valid and reliable for many SLE relevant 
domains. Importantly, PROMIS scores did not correlate well with physician-
derived measures. This disconnect between objective signs and symptoms 
and the subjective patient disease experience underscores the crucial need to 
integrate PROs into clinical care to ensure optimal disease management. 
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CHAPTER ONE 
The Feasibility of Patient Reported Outcome Measurement Information 
System (PROMIS) in Systemic Lupus Erythematosus 
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INTRODUCTION 
The evaluation of patient reported outcomes (PROs) is a priority in systemic 
lupus erythematosus (SLE), a chronic autoimmune disease with involvement 
of multiple organ systems and significant impact on quality of life. PROs are 
recognized as an independent outcome measure in SLE, alongside disease 
activity and damage, and their assessment is required in clinical trials.1–3 
Historically, SLE PRO measures have been primarily designed for research 
purposes, but there is increasing interest in measuring PROs to enhance 
clinical care in SLE.4,5 The routine capture of PROs can promote the provision 
of patient-centered care and performance improvement by facilitating patient-
provider communication, informing treatment decisions, and tracking 
outcomes.6 Identifying and evaluating validated PRO measures for use at the 
point of care is thus a priority.  
 
Patient Reported Outcome Measurement Information System (PROMIS) is a 
National Institutes of Health funded initiative which created item banks of 
questions in various domains to evaluate PROs across health conditions.7 
PROMIS instruments include computerized adaptive tests (CATs), which 
utilize item response theory to reduce responder burden and can be easily 
scored at the point of care. PROMIS has numerous CATs in domains of 
relevance to SLE patients that have potential utility in measuring PROs in both 
research and clinical settings. While the feasibility of administering PROMIS 
CATs to outpatients with rheumatic conditions such as scleroderma and 
rheumatoid arthritis has been demonstrated, to date there are no studies 
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evaluating PROMIS CATs in SLE.8,9 The validation of PROMIS CATs is 
described in chapter 2, and here we describe the feasibility of administering 
PROMIS CATs to SLE outpatients participating in the validation study.  
 
METHODS 
Population- English speaking adults ages 18 years or older receiving care at 
the Hospital for Special Surgery (HSS) Lupus Center of Excellence and 
meeting 4 or more American College of Rheumatology 1997 SLE Criteria were 
eligible to participate in the validation study.10 Patients with active malignancy 
other than non-melanomatous skin cancer and those receiving current dialysis 
treatment were excluded.  
 
Patient Recruitment and Enrollment- Lupus patients were identified by treating 
rheumatologists and medical records were screened to confirm eligibility. 
Patients were approached at the time of their outpatient visit and were invited 
to participate in a study validating PROMIS CATs in SLE. They were offered 
the option of completing the web-based surveys on-site or remotely via an 
emailed study-specific URL. Consenting subjects were registered in 
Assessment Center (www.assessmentcenter.net), a free secure online 
research management tool maintained at the Northwestern University 
Research Data Center, at the time of their visit.  
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Initial Assessment- Participants completed PROMIS CATs and legacy PRO 
measures at the time of enrollment either on-site via computer or iPad, or 
remotely using a device of their choice. Subjects who opted to complete the 
assessment off-site were emailed a personalized URL to the questionnaire. 
Subjects who had not completed the assessment by the following day were 
contacted by phone and/or email with a reminder about the questionnaire and 
offered assistance with any technical difficulties. Subjects who did not 
complete the assessment despite the initial reminder were reminded a second 
time by phone or email. Those who did not complete the assessment after two 
reminders were re-approached about the questionnaire at a subsequent 
clinical visit. 
 
Retest Assessment- Participants were contacted by phone and email within 
one week of enrollment to complete PROMIS CATs a second time for 
evaluation of retest reliability. Subjects were again reminded up to two times to 
complete the assessment. 
 
PRO Measures- Fourteen PROMIS CATs were administered as part of the 
validation study: Physical Function (version 1.2), Mobility (v.1.2), Pain 
Behavior (v.1.0), Pain Interference (v1.1), Ability to Participate in Social Roles 
(v2.0), Satisfaction with Social Roles and Activities (v2.0), Fatigue (v1.0), 
Sleep Disturbance (v1.0), Sleep-Related Impairment (v1.0), Applied Cognition-
Abilities (v1.0), Applied Cognition-General Concerns (v1.0), Anger (v1.1), 
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Anxiety (v1.0), and Depression (v1.0). CATs were programmed to administer 
enough items to achieve a standard error (precision estimate) of less than or 
equal to 0.3, corresponding to a reliability of over 0.9 with a minimum of 4 to a 
maximum of 12 items per CAT. Patients completed two legacy PRO 
measures: the SF-36 Standard, US version 1.0, and the LupusQoL-US.11,12 
Order of instrument administration was randomized.  
 
Experience Questions- Following completion of the PRO measures in the 
initial assessment, subjects were asked free response questions about their 
experience completing the questionnaire. They were asked to comment on 
what, if any, difficulties they had completing the survey and what they liked 
about the survey. 
 
Data Collection- All study questionnaires, including PROMIS CATs and legacy 
PRO instruments, were administered through Assessment Center. Socio-
demographic information including age, sex, race, ethnicity, employment and 
disability status, education, and insurance type were obtained by patient self-
report. Disease duration and medications at the time of enrollment were 
derived from participants’ medical records, while disease activity and damage 
as measured by SELENA-SLEDAI13 and SLICC/ACR damage index14 was 
provided by the subjects’ treating rheumatologists. All information was entered 
into Assessment Center. 
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Statistical Analysis- Means and standard deviations were calculated for 
continuous variables, and frequencies and percentages for categorical 
variables. Differences in baseline demographics and disease characteristics 
between participating and non-participating patients were assessed using T-
tests and chi-square tests as appropriate. Differences in baseline 
characteristics were also assessed between patients who completed retest 
assessments and those who did not. All statistical analyses were performed 
with SAS version 9.3 (Cary, NC, USA). 
 
The study was reviewed and approved by the HSS Institutional Review Board. 
 
RESULTS 
Initial Assessment- Over thirteen months, 238 eligible patients were 
approached to participate in the study, with 229 patients consenting to 
participate (Figure 1.1). Among the 9 patients who declined to participate, time 
constraints was the reason most frequently cited. Of the remaining patients 
who declined two cited discomfort with computers, one cited a recent injury, 
one cited discomfort participating in research studies, and one declined 
because he “did not want to think about lupus symptoms.”  
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Figure 1.1 Study Flow Chart 
 
Two hundred and four subjects went on to complete the initial assessment 
after consenting, with 164 (80.4%) completing the questionnaire remotely 
using computers, tablets, or smartphones. Of the 25 patients who consented 
and did not complete an assessment, 2 withdrew consent from the study, 4 
partially completed the questionnaires, and 1 died. Of the 18 remaining 
subjects who did not complete the assessment many cited time constraints as 
the reason for not completing the questionnaire during reminder phone 
* Of eligible subjects. 
229 (96%) 
Consented 
204 (86%) 
Completed 
Assessment 
162 (79%)* 
Completed 
Retest 
25 (10%)  
Did Not 
Complete 
Assessment 
9 (4%)  
Declined 
2 Withdrew Consent; 
1 Died; 
4 Partially Completed; 
18 Did Not Complete 
4 Time 
Constraints; 
2 Tech 
Discomfort; 
3 Other 
238 SLE 
Patients  
Approached 
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conversations. The majority of consenting subjects who completed the initial 
assessment did not require reminders (Figure 1.2).  
 
Figure 1.2 Reminders Required for Initial Assessment 
 
Of the 67 subjects (32.8%) who did require reminders, 41 (61.2%) completed 
the assessment after one reminder, 17 (25.4%) required 2 reminders, and 9 
(13.4%) required a third reminder at a subsequent clinical visit. There were no 
statistically significant differences in demographic or clinical characteristics 
between subjects who completed the initial assessments and those who did 
not (Table 1.1), though there was a non-statistically significant trend towards 
longer disease duration and less frequent renal involvement in non-completers 
(p = 0.07). 
Assessment 
Completed 
(204) 
No 
Reminders 
(137) 
Reminders 
(67) 
1 Reminder  
(41) 
Phone 
Conversation  
(26) 
Voicemail + 
Email (13) 
Email                
(2) 
2 Reminders 
(17) 
2 Phone 
Conversations 
(17) 
3 Reminders  
(9) 
2 Phone 
Conversations 
+ Follow Up at 
Visit (9) 
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Table 1.1 Characteristics of Subjects Completing vs. Not Completing 
Initial and Retest Assessments 
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Subjects completing the initial assessment had variable levels of education 
and employment status, with one third of participants reporting receiving 
disability benefit at the time of enrollment (Table 1.2). Participants self-
reported high rates of use of technology, with over 80% reporting regular use 
of a smartphone and nearly as many (77.7%) reporting daily use of email. 
 
Table 1.2 Additional Characteristics of Participating Subjects (n = 204) 
Characteristic n (%) 
Education  
High School or less 34 (16.7) 
Some College 49 (24.1) 
College or Beyond 120 (59.1) 
Employment  
Employed- Full Time 74 (36.3) 
Employed- Part Time 22 (10.8) 
Student 15 (7.4) 
On disability 67 (33.0) 
Use of Technology  
Computer 148 (72.9) 
Tablet 100 (49.3) 
Smartphone 172 (84.7) 
None of the Above 7 (3.4) 
Daily Use of Email 157 (77.7) 
 
Time required to complete the initial assessment varied among subjects- the 
SF-36 took subjects an average of 6.6 minutes (median = 5.2), the LupusQoL 
took an average of 5.9 minutes (median = 4.6), and the 14 PROMIS CATs 
took an average of 11.3 minutes (median = 7.4). 
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Retest Assessment- One hundred and sixty two subjects (79% of those 
eligible) completed a retest assessment within one week of the initial 
assessment. Most of these subjects required a reminder to complete the 
questionnaire, with 78 (48.1%) requiring one reminder and 51 (31.5%) 
requiring two reminders (Figure 1.3).  
 
Patients who completed the retest were more frequently non-Hispanic than 
those who did not (73.5% vs. 64.3%, p = 0.04) and had less frequent renal 
involvement by ACR classification criteria than those who did not (42% vs. 
61.9%, p = 0.02). They were also less likely to be flaring by SELENA-SLEDAI 
definition of flare (16.7% vs. 31%, p = 0.03). There were no other statistically 
significant differences in demographic or clinical characteristics between the 
two groups (Table 1.1). 
Retest 
Completed 
(162) 
No 
Reminders 
(33) 
Reminders 
(129) 
1 Reminder  
(78) 
Email (56) 
Phone 
Conversation  
(22) 
2 Reminders 
(51) 
2 Phone 
Conversations 
(3) 
Email + Phone 
Conversation 
(44) 
2 Emails 
(4) 
Figure 1.3 Reminders Required for Retest 
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Experience- A majority of subjects reported a positive experience completing 
the questionnaires. Of the 204 subjects completing the initial assessment, 155 
commented on aspects of the survey that they liked. Comments related to the 
content of questions were most frequent, with over 25 subjects praising the 
concise, clear, detailed, and thorough nature of the questions. Many cited the 
relevance of the questions- “you get to the heart of the disease symptoms.” 
Four participants specifically commented on appreciating the inclusion of 
emotional and mental health questions in the survey. Many also cited the 
format of the assessment as a positive, with 15 describing it as “easy” or 
“user-friendly,” 6 appreciating the multiple choice format, and 5 citing the 
online nature of the survey as a positive, since it could be done on “private 
time” or at home. 
 
Many participants appreciated the validating and self-reflective aspects of the 
survey with over 20 subjects specifically commenting on these areas. One 
subject noted the survey “made me think about how lupus affects me, made 
me think about how I am really feeling, ”while others stated the survey 
“showed me things that I did not realize have affected me” and “made me 
more aware of my lifestyle.” Validation was a recurrent theme with one subject 
reflecting: “Every question applied so accurately to me personally, there was a 
strange satisfaction especially after having it take so many years before I was 
properly diagnosed. That even after so many years that NONE of it is 
imaginary or overblown alleviates any guilt or doubt that I might now or have 
ever felt about how I’m feeling or have felt in the past.” Another explained that 
the survey was “very appropriate for lupus issues that people don’t believe or 
are hard for the patient to voice to a doctor or a loved one. I often feel stupid 
 16 
and I am not because I can’t remember a word or something is on the tip of 
my tongue. It is embarrassing and frustrating. It is validating to be asked about 
it.” Others noted “it is refreshing to know that someone cares” and that the 
survey “gave me a sense of support.” 
 
Eighty-two participants commented on challenges completing the survey. The 
most common difficulty was technical, with 7 subjects reporting error 
messages from Assessment Center. Six subjects felt the survey was too long 
with 3 citing the repetitiveness of questions and two noting that a progress bar 
would be helpful. Four subjects had difficulty understanding the questions, with 
4 reporting the variation of time frame in the questions was confusing and 4 
noting the questions were at times vague. Five subjects wanted more room to 
explain their responses or add comments, and one felt that an interview would 
be more appropriate for gathering this information. Several subjects reported 
symptoms while completing the survey including pain in the fingers/hands (2), 
neck/shoulder pain (1), difficulty seeing the screen (1), sleepiness (2), and 
difficulty concentrating (3). One subject noted difficulty “talking and thinking 
about lupus- denial is somewhat more comfy.” 
 
 
DISCUSSION 
This study is the first to demonstrate the feasibility of administering PROMIS 
CATs to SLE outpatients. Over 85% of a diverse group of SLE patients 
approached to participate in the study completed an assessment, the majority 
without any reminders, and nearly 80% of those went on to complete the retest 
assessment one week later.  
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There were no significant demographic differences between patients 
completing an assessment and those who did not, suggesting that PROMIS 
CATs are feasible in patients with diverse backgrounds, including those 
without a college degree (31%), those on disability (33%), and those insured 
by Medicaid (36%). There were also no significant differences in disease 
characteristics between those completing the surveys and those who did not, 
suggesting that patients with mucocutaneous lupus were as likely to complete 
the survey as those with visceral organ involvement. Arthritis and 
concentration difficulties were raised by a small number of participants, but 
overall did not preclude completion of the survey. There were larger 
percentages of Hispanics and subjects with history of renal involvement 
among those who did not complete the retest assessment. This will need to be 
further explored in focused interviews with subjects and/or in larger studies, 
particularly because this finding was undercut by an opposing trend in subjects 
completing the initial assessment. Importantly, flaring subjects were somewhat 
less likely to complete the retest, which raises a concern of feasibility of 
longitudinal evaluation patients with more active disease. This will need to be 
more thoroughly investigated in larger studies over a longer period of time. 
 
Subjects had overwhelmingly positive experiences completing the assessment 
as evidenced by their qualitative feedback. The questions were felt to be 
relevant, thorough, clear, and concise and the format of online multiple-choice 
questions was welcomed. Perhaps most importantly, patients commented on 
the value of completing the assessments, citing the benefits of self-reflection 
and feelings of validation in being asked about issues relevant to their 
experience. The promotion of self-reflection and validation through completion 
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of PROs may be an important mechanism in enhancing patient engagement 
and satisfaction with their health care experience. 
 
Challenges raised by subjects most commonly related to technical difficulties, 
as Assessment Center occasionally prematurely ended the survey. 
Assessment Center will need to be optimized or new vehicles for CAT 
administration will need to be developed to minimize these difficulties in larger 
scale use of CATs in research or routine clinical care. The length of the 
survey, which took subjects over 20 minutes on average, was the second most 
frequent concern raised. This is unlikely to be an issue in the routine use of 
PROMIS CATs in SLE, as this study included redundant PROMIS CATs (i.e. 
physical function and mobility) and both the SF-36 and LupusQoL as part of 
the validation protocol. Each PROMIS CAT averaged less than one minute in 
length, which will likely be a tolerable responder burden, though further 
implementation studies are necessary. 
 
This study has many strengths, including robust rates of enrollment and study 
completion. The high rate of participation in this study is particularly notable as 
recruitment of SLE patients in clinical trials is often difficult, with termination of 
trials due to insufficient enrollment.15 Reasons for poor enrollment in SLE 
prevention trials have been studied and include concerns about current health 
status, trial design, including randomization and medications, and personal 
factors.16 The lack of invasive interventions and randomization in this study 
may have mitigated some of these concerns, but the high participation rate 
may also reflect SLE patients underlying interest in being asked to share their 
experience, reinforcing the importance of assessing PROs. Similar findings 
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were shown in a study evaluating the feasibility of collecting serial electronic 
PROs (SF-36 and the Hospital Anxiety and Depression scale) in French 
patients with chronic inflammatory diseases, including 58 patients with SLE.17 
Ninety-six percent of patients approached consented and 89% went on to 
complete the first assessment with a 13% attrition rate over 6 months. The 
main reason for non-completion was “being too busy.” Similarly, a longitudinal 
validation study of the Lupus Impact Tracker, a lupus specific PRO measure, 
showed a 92% completion rate of retest surveys.18 
 
A further strength of this study is the rigorous comparisons of characteristics 
between responders and non-responders, which has not been performed in 
previous studies of PROMIS CATs or SLE-specific PROs. This analysis, which 
showed no significant difference in demographic or clinical characteristics 
between the two groups, shows that PROMIS CATs can be successfully 
administered to diverse patients with SLE. The inclusion of qualitative data 
evaluating the experience of completing PROMIS CATs is a further strength of 
this study and captures the importance of measuring PROs in validating the 
patient experience.  
 
There are certain limitations to this study. The feasibility of PROMIS CATs was 
evaluated in the context of a validation of study in which subjects were 
administered additional legacy PRO instruments. Thus, completion rates and 
experience comments do not reflect the experience of completing PROMIS 
CATs in isolation. Secondly, this study was conducted in a population of 
English-speakers with relatively high comfort with technology. Further studies
 20 
will need to be performed in non-English speakers and in populations with 
varied familiarity with electronic devices.  
 
Despite these limitations, this study demonstrates the feasibility and 
importance of administering PROMIS CATs to SLE outpatients. With their 
SLE-relevant domains and previously proven superior performance 
characteristics, PROMIS CATs have great potential for capturing PROs in 
settings related to both research and clinical care. Future studies are needed 
to evaluate the feasibility of longitudinal collection of PROMIS CATs and their 
impact on clinical decision-making, patient-provider communication, patient 
engagement and satisfaction 
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CHAPTER TWO 
The Validity of Patient Reported Outcome Measurement Information System 
(PROMIS) in Systemic Lupus Erythematosus 
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INTRODUCTION 
The accurate measurement of health related quality of life (HRQOL), an 
important patient reported outcome (PRO), is critical to providing patient-
centered care. This is especially important in diseases such as systemic lupus 
erythematosus (SLE), in which dramatically lower mortality rates have 
refocused care on minimizing morbidity.1 It is well known that SLE significantly 
decreases HRQOL.2 However, how HRQOL should best be defined and 
measured is unclear, as physicians and patients have differing perceptions of 
the impact of SLE: patients focus on functional status whereas physicians 
focus on laboratory values.3 
 
The United States Food and Drug Administration, the European Medical 
League, and the Outcome Measures in Rheumatology Clinical Trials 
(OMERACT) group have identified HRQOL as a crucial outcome measure for 
clinical trials and observational studies in SLE.4–6 They recommend the use of 
both generic and disease-specific measures to allow comparisons with healthy 
individuals while evaluating health utilities that are meaningful to patients. 
 
Numerous generic and disease specific instruments have been validated for 
the measurement of PROs in SLE, but all have important limitations.7,8 The 
Medical Outcomes Survey Short Form 36 (SF-36)9 is a widely used generic 
measure in SLE, but has variable longitudinal responsiveness10–12 and lacks 
multiple domains of relevance to lupus patients, such as fatigue, sleep, and 
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cognition.13–15 The LupusQoL, the most extensively validated SLE-specific 
instrument, includes several of these SLE-specific domains, including fatigue, 
body image and planning, but has significant floor and ceiling effects.16 In 
addition, both measures are difficult to administer and score at the point of 
care. 
 
The Patient Reported Outcome Measurement Information System (PROMIS) 
is a novel psychometrically validated system developed by the National 
Institutes of Health to efficiently measure PROs in populations with a wide 
range of chronic diseases.17 PROMIS instruments increase measurement 
precision and reduce responder burden relative to traditional instruments as 
they were developed using item response theory and include computerized 
adaptive tests (CATs). CATs select the most informative questions from an 
item bank based on subjects’ previous responses, permitting the use of fewer 
questions per domain with more precision.  PROMIS item banks are generic, 
scored with T scores normalized to the general population in the United 
States, and include numerous domains of relevance to SLE patients that are 
not found in the SF-36, including CATs related to fatigue, sleep and cognition.   
 
The performance characteristics of PROMIS CATs have not yet been 
demonstrated in SLE. This study describes the validity and reliability of 14 
PROMIS CATs compared to both the SF-36 and LupusQoL in adult SLE 
outpatients. 
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METHODS 
Population- English speaking adults ages 18 years or older receiving care at 
the Hospital for Special Surgery (HSS) Lupus Center of Excellence and 
meeting 4 or more American College of Rheumatology 1997 SLE Criteria were 
eligible to participate.18 Patients with active malignancy, other than non-
melanomatous skin cancer, and those currently on dialysis were excluded.  
 
Enrollment- Lupus patients were identified by treating rheumatologists, and 
medical records were screened to confirm eligibility. Patients were invited to 
participate in the study and consented at the time of an outpatient visit. 
Patients were able to complete the web-based surveys on-site during their 
outpatient visit via computer or iPad with the assistance of a study member.  
Alternatively, patients were given the option of completing the study questions 
remotely on computer, tablet, or smartphone via an emailed study-specific 
URL. Consenting subjects were registered in Assessment Center 
(www.assessmentcenter.net), a free secure online research management tool 
maintained at the Northwestern University Research Data Center.  
 
Data Collection- All study questionnaires, including PROMIS CATs and SF-36 
and LupusQoL (the latter two to be referred to as “legacy PRO instruments”), 
were administered through Assessment Center.  Socio-demographic 
information including age, sex, race, ethnicity, employment and disability 
status, insurance type, and relevant comorbidities were obtained by patient 
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self-report. Disease duration and medications at the time of enrollment were 
derived from participants’ medical records. Disease activity and damage were 
assessed by the subject’s treating rheumatologist using the Safety of 
Estrogens in Lupus Erythematosus-National Assessment-Systemic Lupus 
Erythematosus Disease Activity Index (SELENA-SLEDAI) and the Systemic 
Lupus International Collaborating Clinics/American College of Rheumatology-
Damage Index (SLICC/ACR-DI) respectively.19,20 SELENA-SLEDAI includes a 
physician global assessment, ranging from 0 to 3, and the SELENA-SLEDAI 
score, ranging from 0 to 105. SLICC/ACR-DI scores range from 0 to 46. 
Higher scores reflect greater disease activity and end organ damage. Half the 
participants were randomly assigned to complete the PROMIS CATs first, and 
the other half completed legacy PRO instruments first.  
 
To assess PROMIS CATs test-retest validity, all participants were contacted 
by telephone or email within one week of enrollment to complete PROMIS 
CATs a second time. A 7 point Likert scale anchor question was used to 
identify any changes in patients’ disease activity: “Compared to when you last 
completed this survey, how would you rate the impact of lupus on your general 
health now? a) Much better now, b) somewhat better now, c) a little better 
now, d) about the same, e) a little worse now, f) somewhat worse now or g) 
much worse now.” 
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PRO Measures- PROMIS CATs were selected based on prior focus group 
studies in which SLE patients identified quality of life domains of critical 
importance.14,15,21 Fourteen CATs were administered: Physical Function 
(version 1.2), Mobility (v.1.2), Pain Behavior (v.1.0), Pain Interference (v1.1), 
Ability to Participate in Social Roles (v2.0), Satisfaction with Social Roles and 
Activities (v2.0), Fatigue (v1.0), Sleep Disturbance (v1.0), Sleep-Related 
Impairment (v1.0), Applied Cognition-Abilities (v1.0), Applied Cognition-
General Concerns (v1.0), Anger (v1.1), Anxiety (v1.0), and Depression (v1.0). 
PROMIS CAT items refer to the seven preceding days, with the exception of 
items in the physical and social health domains, which do not specify a recall 
time frame. CATs were programmed to administer enough items to achieve a 
standard error (precision estimate) of less than or equal to 0.3, corresponding 
to a reliability > 0.9 with a minimum of 4 to a maximum of 12 items per CAT. 
Patients completed two legacy PRO measures: the SF-36 Standard, US 
version 1.0, a frequently utilized generic PRO instrument validated for use in 
lupus clinical trials, and the LupusQoL-US, an extensively validated lupus 
specific PRO questionnaire adapted for use in the United States.9,22 Both 
legacy instruments referred to a four-week recall period. 
 
PROMIS CATs were scored through Assessment Center using a T score 
metric, where the mean T score in the US general population is 50 with a 
standard deviation of 10. Higher T scores reflect more of the trait being 
measured, so that higher scores for physical and social function are desirable, 
 30 
whereas higher symptom scores indicate a greater burden of symptoms. The 
SF-36 is divided into 8 scales, each with a score ranging from 0 to 100, with 
higher scores reflecting better health related quality of life (HRQOL). Scores 
are summarized in the Physical Component Summary (PCS) and Mental 
Component Summary (MCS), which are normalized to the general US 
population with a mean score of 50 and standard deviation of 10. The 
LupusQoL contains 34 questions in 8 domains, with scores ranging from 0 to 
100, with higher scores indicating better HRQOL. 
 
Statistical Analysis- Means and standard deviations were calculated for 
continuous variables, and frequencies and percentages for categorical 
variables. Score distributions are described with means, standard deviations, 
medians, 25th and 75th percentiles and ranges. Floor and ceiling effects for 
each instrument were analyzed by calculating the percentage of respondents 
achieving the minimum and maximum possible scores respectively. 
Convergent validity between PROMIS CATs and legacy PRO instruments was 
assessed with Spearman’s correlation coefficients (r), with coefficients of at 
least 0.7 indicating good convergent validity. Correlation between PROMIS 
CATs and disease activity and damage measures were also evaluated with 
Spearman’s r. Test-retest reliability was evaluated in participants completing 
two questionnaires within the seven day time frame who indicated “about the 
same” in their condition on the anchor question. Agreement between scores 
for each questionnaire was assessed with interclass correlation coefficient 
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(ICC). ICCs of at least 0.7 indicate acceptable test-retest reliability. All 
statistical analyses were performed with SAS version 9.3 (Cary, NC, USA). 
 
The study was reviewed and approved by the HSS Institutional Review Board. 
 
RESULTS 
Population- Of 238 eligible SLE patients invited to participate in the study, 229 
consented and 204 (86%) completed the questionnaires. Among the 204 
participants, 162 (79%) completed the retest within one week. A diverse cohort 
of patients participated in the study (Table 2.1).  Subjects were predominantly 
female (93%) with mean (SD) age of 40.0 (13.2) years. A majority of 
participants were non-white (62.3%) and over one quarter identified as 
Hispanic or Latino (28.4%). Over 40% of subjects were insured by Medicare or 
Medicaid, with 47.1% working full or part-time and one third reporting receiving 
disability benefits. With regard to SLE disease characteristics, the average 
(SD) disease duration was 12.2 (8.8) years, and the most common clinical 
classification criteria were arthritis (81%), renal manifestations (46%), and 
photosensitivity (45%). The average (SD) SELENA-SLEDAI score was 4.2 
(3.5), indicating mild disease activity, though 19.6% were flaring per SELENA-
SLEDAI at the time of assessment. The mean (SD) SLICC/ACR-DI was 1.2 
(1.7). 
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Table 2.1 Characteristics of Participants (n = 204) 
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Table 2.1 Characteristics of Participants (n = 204) 
 
Characteristic Value 
Age: mean ± SD years, (range) 40.0 ± 13.2, (19 -
73) 
Female: n (%) 189 (92.6) 
Race: n (%)   
White 77 (37.7) 
Black 61 (29.9) 
Asian 26 (12.8) 
Other 40 (19.6) 
Ethnicity:  Hispanic/Latino: n (%)  58 (28.4) 
Insurance: n (%)   
Medicaid 73 (35.8) 
Medicare 21 (10.3) 
Private 110 (53.9) 
Employment: Full or Part-Time: n (%) 96 (47.1) 
Disability: n (%) 67 (33.0) 
Comorbidities: n (%) 
 
Anxiety 58 (28.4) 
Depression 56 (27.5) 
Fibromyalgia 29 (14.2) 
ACR Classification Criteria: n (%) 
 
Malar Rash 80 (39.2) 
Discoid Rash 21 (10.3) 
Photosensitivity 92 (45.1) 
Ulcers 60 (29.4) 
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Table 2.1 Continued  
 
Characteristic Value 
Arthritis 165 (80.9) 
Serositis 67 (32.8) 
Renal  94 (46.1) 
Neurologic 19 (9.2) 
Hematologic 101 (49.5) 
Immunologic 178 (87.3) 
ANA 204 (100) 
Medications: n (%)   
Current Steroid Use 118 (58.1) 
Current Hydroxychloroquine Use 170 (85.9) 
Current Immunosuppressive Use 138 (69.7) 
Disease Duration: mean ± SD years, (range) 12.2 ± 8.8, (0 - 48) 
Physician Global Assessment: mean ± SD, 
(range) 
[Range 0 to 3, higher is worse] 
0.8 ± 0.6, (0 – 2.8) 
SELENA-SLEDAI: mean ± SD, (range) 
[Range 0 to 105, higher is worse] 
4.2 ± 3.5, (0 – 20) 
SELENA-SLEDAI Flare: n (%) 40 (19.6) 
SLICC: mean ± SD, (range) 
[Range 0 to 46, higher is worse] 
1.2 ± 1.7 (0 – 8) 
	
 
PROs- PROMIS CAT and legacy instrument score distributions are shown in 
Table 2.2. The mean scores were worse than the general population across all 
PROMIS domains. Mean SF-36 PCS and MCS scores were 1.4 and 0.7 SD 
worse than the general population. Mean LupusQoL scores across domains 
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were 10 to 20 points higher than published benchmarks for SLE patients in the 
U.S.23 Subjects with self-reported anxiety, depression, or fibromyalgia scored 
worse than those without these comorbid conditions across all PROMIS 
domains. Subjects with self-reported fibromyalgia scored one standard 
deviation worse in the pain interference and ability to participate in social roles 
CATs than those without (p-value < 0.001). Subjects with self-reported anxiety 
and depression scored one standard deviation worse in the anger, anxiety, 
and depression CATs than those without (p-value <0.001). 
PROMIS CATs were generally normally distributed, except for pain behavior 
and fatigue, which had slight positive skews. Similarly, SF-36 scale scores 
were relatively normally distributed except for the physical function, role 
physical and role emotional scales, which were positively skewed. All domains 
in the LupusQoL were positively skewed. The SF-36 had large floor and 
ceiling effects in the role physical and role emotional scales (23–50%), while 
the LupusQoL had notable ceiling effects across all domains (6-32%). 
PROMIS CATs had no floor or ceiling effects.  
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Table 2.2 PROMIS CAT and Legacy PRO Instrument Score Distribution 
(n = 204)
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The number of items and time per instrument are shown in Table 2.3. On 
average PROMIS CATs administered 4 items per domain and the median time 
per CAT was 32 seconds. 
 
Correlations of PROMIS CATs with Legacy Instruments- Correlations between 
PROMIS CATs and legacy instruments are shown in Table 2.4. PROMIS 
physical function and mobility CATs correlated strongly with the physical 
function domains in the SF-36 and LupusQoL (r = 0.81 - 0.86, p-value < 
0.0001), and moderately with the SF-36 PCS (r  = 0.49 - 0.52, p-value < 
0.0001). Correlations between PROMIS pain interference and legacy 
instrument pain domains were also strong (|r| = 0.79, p-value < 0.0001). 
PROMIS fatigue correlated better with the corresponding domain in the 
LupusQoL (|r| = 0.75, p-value < 0.0001) than with the SF-36 vitality scale (|r| = 
0.67, p-value < 0.0001). Similarly, in the domain of mental health, PROMIS 
anger, anxiety, and depression CATS showed strong correlations with the 
LupusQoL emotional health domain (|r| = 0.69 – 0.75, p-value < 0.0001), but 
poor to moderate correlations with all of the SF-36 mental health related 
scales (|r| = 0.29 – 0.68, p-value < 0.0001). PROMIS social function CATs 
correlated moderately to strongly with the corresponding domains in the SF-36 
and LupusQoL (|r| = 0.55 – 0.75).  
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Table 2.3 Items and Time per Instrument 
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Table 2.4 Correlations Between PROMIS CATs and Legacy PRO Instruments 
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Table 2.4  
 
PROMIS CAT Legacy Instrument/Domain Spearman’s r* 
Physical Function SF-36/Physical Function 0.83 
 
SF-36/Role Physical 0.65 
 
SF-36/Physical Component 
Summary 
0.49 
 
LupusQoL/Physical Health 0.82 
Mobility SF-36/Physical Function 0.86 
 
SF-36/Role Physical 0.55 
 
SF-36/Physical Component 
Summary 
0.52 
 
LupusQoL/Physical Health 0.81 
Pain Interference SF-36/Bodily Pain 0.79 
 
LupusQoL/Pain -0.79 
Pain Behavior SF-36/Bodily Pain 0.70 
 
LupusQoL/Pain -0.71 
Fatigue SF-36/Vitality -0.67 
 
LupusQoL/Fatigue -0.75 
Anger SF-36/Mental Health -0.29 
 
SF-36/Role Emotional -0.50 
 
SF-36/Mental Component 
Summary 
-0.58 
 
LupusQoL/Emotional Health -0.69 
Anxiety SF-36/Mental Health -0.35 
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Table 2.4 Continued  
 
PROMIS CAT Legacy Instrument/Domain Spearman’s r* 
 
SF-36/Role Emotional -0.49 
 
SF-36/Mental Component 
Summary 
-0.60 
 
LupusQoL/Emotional Health -0.75 
Depression SF-36/Mental Health -0.33 
 
SF-36/Role Emotional -0.59 
 
SF-36/Mental Component 
Summary 
-0.68 
 
LupusQoL/Emotional Health -0.75 
Ability to 
Participate in 
Social Roles 
SF-36/Social Function 0.72 
 
LupusQoL/Planning 0.75 
Satisfaction with 
Social Roles 
SF-36/Social Function 0.60 
 
LupusQoL/Planning 0.55 
 
*p-value < 0.0001 
 
There were no analogous legacy instrument domains to which to compare the 
four PROMIS CATS evaluating cognition and sleep. However, these CATs 
showed strong correlations with fatigue. Correlations between fatigue and 
sleep impairment and applied cognition-concerns were both 0.68, while 
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correlations between sleep interference and disturbance was 0.62, and 
applied cognition-abilities and concerns was -0.74 (p-value <0.001 for all).  
Correlations of PROMIS CATs with Physician-Derived Measures: Correlations 
between PROMIS CATs and physician-derived measures of lupus disease 
activity and disease-related damage are shown in Table 2.5. Correlations were 
generally weak and non-significant, with the highest correlations observed 
between CATs in the domains of physical function and pain and the physician 
global assessment and SLICC/ACR-DI (|r| = 0.27 to 0.37, p-value <0.0001).  
 
Table 2.5 Correlations Between PROMIS CATs and Physician Derived 
Measures 
 
PROMIS CAT Physician 
Global 
SELENA-
SLEDAI 
SLICC-ACR DI  
Physical Function -0.29* -0.15 -0.27* 
Mobility -0.35* -0.16 -0.31* 
Pain Behavior 0.31* 0.16 0.22 
Pain Interference 0.37* 0.22 0.20 
Fatigue 0.26 0.19 0.05 
Anger 0.26* 0.21 0.07 
Anxiety 0.24 0.17 0.12 
Depression 0.24 0.17 0.10 
Ability to Participate 
in Social Roles 
-0.28* -0.17 -0.13 
Satisfaction with 
Social Roles 
-0.22 -0.14 -0.08 
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Table 2.5 Continued  
 
PROMIS CAT Physician 
Global 
SELENA-
SLEDAI 
SLICC-ACR DI  
Cognitive Abilities -0.24 -0.16 -0.12 
Cognitive Concerns 0.22 0.18 0.09 
Sleep Disturbance 0.25 0.10 0.11 
Sleep-Related Impairment 0.16 0.13 0.10 
 
*p-value ≤ 0.0001. 
 
Reliability: Of the 162 participants who completed PROMIS CATs a second 
time within 7 days of the initial assessment, 90 reported no change in the 
impact of lupus on their health. Among these 90 subjects, ICCs were greater 
than 0.7 across all domains (Table 2.6). 
 
Table 2.6. Test-Retest Reliability of PROMIS CATs (n = 90*) 
 
PROMIS CAT ICC SEM  
Physical Function 0.86 3.17 
Mobility 0.88 2.91 
Pain Behavior 0.80 4.37 
Pain Interference 0.86 4.01 
Fatigue 0.84 3.94 
Anger 0.72 5.87 
Anxiety 0.78 4.46 
Depression 0.86 3.92 
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Table 2.6 Continued  
 
PROMIS CAT ICC SEM  
Ability to Participate in Social 
Roles 
0.87 3.52 
Satisfaction with Social Roles 0.78 5.17 
Cognitive Abilities 0.83 4.21 
Cognitive Concerns 0.83 5.73 
Sleep Disturbance 0.88 3.83 
Sleep-Related Impairment 0.80 4.85 
 
*Number of participants reporting no change in impact of lupus on health at 
second assessment. 
 
DISCUSSION 
This study is the first to demonstrate the validity and reliability of PROMIS 
CATs in SLE outpatients. PROMIS CATs showed strong correlations with the 
SF-36 and LupusQoL across analogous domains, supporting the construct 
validity of the measures. PROMIS CATs showed high test-retest reliability in 
participants self-reporting no change in the impact of lupus on their health. 
 
 Although to our knowledge no prior studies have evaluated PROMIS CATs in 
adults with SLE, PROMIS short forms, i.e. PROMIS items administered as 
regular questionnaires, without using computerized adaptive testing, have 
been evaluated in SLE patients.  The PROMIS-29, a 29 question short form 
composed of items from seven PROMIS item banks (physical function, fatigue, 
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pain interference, anxiety, depression, sleep disturbance, and satisfaction with 
social roles), was evaluated in 333 patients with self-reported SLE, recruited 
from patient advocacy organizations.24 The PROMIS-29 domain scores were 
found to correlate with self-reported disease severity. Mahieu et al evaluated 
the internal consistency of seven PROMIS short forms (physical function, 
fatigue, pain interference, anxiety, depression, sleep disturbance, and sleep-
related impairment) in 123 adults with SLE, finding strong internal consistency 
among the measures (Cronbach’s alpha 0.91 to 0.98).25 They also showed 
strong correlations between PROMIS fatigue short form and the self-report 
Fatigue Severity Scale scores (Spearman’s r = 0.84, p-value < 0.0001). The 
authors found that physical activity, measured with an accelerometer, was 
positively associated with PROMIS physical function (r = 0.33, p-value = 
0.0003) and negatively associated with pain interference (r = -0.29, p-value = 
0.001). PROMIS pediatric short forms have also demonstrated construct 
validity and responsiveness in 100 children with lupus.23  
 
In this study, the first to evaluate PROMIS CATs in SLE, participants scored 
one half standard deviation or more worse than the general population across 
most PROMIS CATs, with the largest differences in the domains of physical 
function, mobility, pain interference, fatigue, sleep-related impairment, and 
applied cognition-concerns. This trend in scores suggests face validity of the 
instruments given the known lower HRQOL in SLE patients.26 These findings 
are also consistent with those of Mahieu et al who reported SLE subjects 
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scored one half standard deviation worse than the general population in 
physical function, pain interference, fatigue, sleep disturbance and sleep-
related impairment short forms, which are scored using the same T scale 
metric as CATs.25 Further, the performance of SLE patients on PROMIS CATs 
is similar to that of patients with other chronic rheumatologic conditions with 
similar mean scores across domains reported in validation studies of PROMIS 
CATs in those populations.27–29 
 
Subjects with anxiety, depression and fibromyalgia scored worse on PROMIS 
CATs than subjects without these comorbidities, with largest difference in pain 
interference and social abilities for those with fibromyalgia, and in emotional 
health for those with anxiety or depression.  This further supports the fact that 
PROMIS CATs have construct validity. Since patients with SLE have a high 
prevalence of comorbid fibromyalgia, anxiety, and depression that can 
contribute negatively to HRQOL, it is reassuring that PROMIS CATs were, on 
average, different between these groups.  
 
While prior studies have suggested that PROMIS short forms appear to have 
good reliability and precision in patients with SLE, this is the first study to 
compare the performance characteristics of PROMIS instruments to the SF-36 
and LupusQoL, two legacy PRO instruments commonly used in clinical 
research. In this study, in contrast to legacy instruments, PROMIS CATs 
demonstrated a normal distribution across domains and notably had no floor 
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or ceiling effects. In lacking floor and ceiling effects, PROMIS CATs are better 
able to discriminate among individuals at the extremes of the spectrum, and 
importantly, may be more sensitive to capturing longitudinal change within 
individuals. The significant floor and ceiling effects observed in the SF-36 and 
LupusQoL are consistent with score distributions reported in other studies and 
may contribute to the variable responsiveness of the measures in longitudinal 
studies.10,12,30 Further, PROMIS CATs demonstrated high precision and 
reliability in this study despite the relatively few questions administered in each 
domain (average of 4 items per domain). The ability of PROMIS CATs to 
decrease responder burden without compromising precision or reliability is a 
significant advantage over legacy instruments. 
 
Importantly, PROMIS CATs correlated poorly with physician-derived measures 
of SLE disease activity, supporting the principle that PROs are an independent 
outcome measure. In SLE, where defining appropriate outcome measures for 
clinical trials remains challenging,31 the patient perspective is particularly 
important. PROMIS CATs are validated precise tools to capture patient-
centered outcomes and complement physician-derived assessments. 
  
Strengths of this study include the large and diverse cohort of subjects with 
classification criteria confirmed SLE. There was a high rate of participation and 
subjects had varied disease activity and severity. Rates of fibromyalgia and 
psychiatric comorbidities in this cohort are similar to those reported in other 
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SLE cohorts, suggesting our results are generalizable.32,33 PROMIS CATs 
were chosen in domains identified as important by SLE patients in prior 
studies, and a large number of CATs were administered.  
 
This study has certain limitations. In an effort to decrease responder burden, 
not all PROMIS domains were validated against equivalent gold standard 
instruments. For example, the sleep and cognition related CATs had no 
corresponding domains in the SF-36 and LupusQoL, so the construct validity 
of these measures was inferred by their correlations with other domains. 
Conversely, PROMIS lacks many domains that are present in the LupusQoL, 
including body image, planning, and intimate relationships, which are known to 
be valued by SLE patients. This points to a gap and these item banks will 
need to be developed. In this study, PROMIS CATs were evaluated in 
outpatients; the validity and responsiveness in inpatients, who may have 
worse HRQOL and worse disease activity, may differ and will need to be 
explored. Importantly, this study is cross-sectional and longitudinal data is 
needed to evaluate the responsiveness of PROMIS CATs across varying 
states of disease activity over time.  
 
In conclusion, this study demonstrates the validity and reliability PROMIS 
CATs in outpatients with SLE. PROMIS CATs provide an easy and accurate 
method of evaluating patient-centered domains in patients with SLE, and 
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could be an important metric for measuring relevant patient domains in both 
clinical research and routine clinical care. 
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